Intravenous immunoglobulin in secondary progressive multiple sclerosis: Randomised placebo-controlled trial

Lancet

Volumn 364, Issue 9440, 2004, Pages 1149-1156

  Hommes, Otto R ^a   Sørensen, Per S ^b   Fazekas, Franz ^c   Enriquez, Monika Maas ^d   Koelmel, Hans W ^e   Fernandez, Oscar ^f   Pozzilli, Carlo ^g   O'Connor, Paul ^h  

^a European Charcot Foundation   (Netherlands)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF GRAZ   (Austria)

^d BAYER AG   (Germany)

^e HELIOS KLINIKUM ERFURT   (Germany)

^f HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; PLACEBO;

ADULT; ARTICLE; BLOOD CLOTTING DISORDER; CHILL; CLINICAL EXAMINATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; FEMALE; FEVER; HEADACHE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENCE RISK; THROMBOEMBOLISM; THROMBOPHLEBITIS; TREATMENT FAILURE;

EID: 4644250609     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)17101-8     Document Type: Article

References (26)

1. Schuller E, Govaerts A. First results of immunotherapy with immunoglobulin G in multiple sclerosis patients. Eur Neurol. 22:1983;205-212
2. Achiron A, Pras E, Gilad R, et al. Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. Arch Neurol. 49:1992;1233-1236
3. Sorensen PS. Intravenous immunoglobulin G therapy: effects of acute and chronic treatment in multiple sclerosis. Mult Scler. 1:1996;349-352
4. Fazekas F, Deisenhammer F, Strasser Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet. 349:1997;589-593
5. Achiron A, Gabbay U, Gilad R, et al. Intravenous immunoglobulin treatment in multiple sclerosis: effect on relapses. Neurology. 50:1998;398-402
6. Sorensen PS, Wanscher B, Jensen CV, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology. 50:1998;1273-1281
7. Lewanska M, Siger-Zajdel M, Selmaj K. No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. Eur J Neurol. 9:2002;565-572
8. Sorensen PS, Fazekas F, Lee M. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neurol. 9:2002;557-563
9. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet. 352:1998;1491-1497
10. Secondary Progressive Efficacy Clinical Trial of Recombinant Inteferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology. 56:2001;1496-1504
11. Goodkin DE, the North American Study Group on Interferon beta-1b in Secondary Progressive MS. Clinical and MRI results of a 3-year randomized controlled trial. Neurology 2000; 54: 2352 (abstr).
12. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology. 59:2002;679-687
13. Hartung HP, Gonsette R, Koenig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double blind, randomised, multicentre trial. Lancet. 360:2002;2018-2025
14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452
15. Fazekas F, Barkhof F, Filippi M, et al. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology. 53:1999;448-456
16. Hommes O, Maas-Enriquez M. ESIMS: an ongoing clinical trial in secondary progressive multiple sclerosis. Mult Scler. 6:(suppl 2):2000;S27-32
17. Goodkin DE, Rudick RA, van der Brug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol. 37:1995;30-40
18. Rudick R, Antel J, Confavreux C, et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol. 42:1997;379-382
19. Molyneux PD, Tofts PS, Fletcher A, et al. Precision and reliability for measurement of change in MRI lesion volume in multiple sclerosis: a comparison of two computer assisted techniques. J Neurol Neurosurg Psychiatry. 65:1998;42-47
20. Weinshenker BG, Issa M, Baskerville J. Meta-analysis of the placebo-treated groups in clinical trials of progressive MS. Neurology. 46:1996;1613-1619
21. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 332:1995;912-917
22. Strasser-Fuchs S, Fazekas F, Deisenhammer F, Nahler G, Mamoli B. The Austrian Immunoglobulin in MS (AIMS) study: final analysis. Mult Scler. 6:(suppl 2):2000;S9-13
23. Comi G, Filippi M, Barkhof F, et al. Early interferon treatment delays conversion to definite MS - ETOMS study: a double-blind, placebo-controlled randomised study. Lancet. 357:2001;1576-1582
24. Sorensen PS, Andersen O, Elovaara I, et al. Double-blind placebo-controlled study of once weekly, low dose interferon beta-1a in secondary progressive multiple sclerosis (SPMS): Nordic SPMS study. Mult Scler. 7:(suppl 1):2001;S94
25. Li DK, Zhao GJ, Paty DW. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology. 56:2001;1505-1513
26. Miller DH, Molyneux PD, Barker GJ, MacManus DG, Moseley IF, Wagner K. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. Ann Neurol. 46:1999;850-859